| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Agilon Health (NYSE:AGL) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 2 | 1 | 0 |
| Last 30D | 1 | 0 | 1 | 1 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Agilon Health and provided 12-month price targets. The average target is $2.4, accompanied by a high estimate of $5.00 and a low estimate of $1.00. Highlighting a 42.86% decrease, the current average has fallen from the previous average price target of $4.20.
The standing of Agilon Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Bill Sutherland | Benchmark | Lowers | Buy | $1.50 | $4.00 |
| Andrew Mok | Barclays | Lowers | Underweight | $1.50 | $3.00 |
| Daniel Grosslight | Citigroup | Lowers | Neutral | $1.00 | $3.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $3.00 | $5.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $5.00 | $6.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agilon Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Agilon Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Agilon Health faced challenges, resulting in a decline of approximately -5.92% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agilon Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -7.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Agilon Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -22.96%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Agilon Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Agilon Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AGL
